Sunovion Pharmaceuticals Inc. is a research-based pharmaceutical company dedicated to discovering, developing and commercializing scientifically advanced therapeutic products that are focused on helping patients suffering from central nervous system and respiratory disorders, as well as other illnesses.
A wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., Sunovion was formed following the merger of Sumitomo Dainippon Pharma's two U.S.-based operations, Sepracor Inc. and Dainippon Sumitomo Pharma America, Inc. The company name, which is representative of the life-affirming energy of the sun and the power of innovation, reflects Sunovion's portfolio of currently marketed pharmaceutical products and pipeline candidates; and serves to emphasize the company's ongoing commitment to improve the lives of patients everywhere.
|7/8/14||Sunovion Pharmaceuticals Inc. Announces Data Published in the CHEST Journal from a One-year, Large Simple Safety Study Evaluating BROVANA® (arformoterol tartrate) Inhalation Solution|
|6/5/14||The Mental Health Listening & Engagement Tour Connects Demi Lovato with Mental Health Advocacy Community|
|5/1/14||Sunovion Pharmaceuticals Inc. to Present New Data on Latuda® (lurasidone HCl) at the 167th Annual Meeting of the American Psychiatric Association|
|4/29/14||Sunovion Pharmaceuticals Inc. Presents Data on Aptiom® (eslicarbazepine acetate) at 66th American Academy of Neurology Annual Meeting|
|4/15/14||Sunovion Pharmaceuticals Inc. Donates Laboratory Equipment to Massachusetts General Hospital to Aid in Research of Neurological Disorders|
|4/7/14||Once-Daily Aptiom® (eslicarbazepine acetate) for the Adjunctive Treatment of Partial-Onset Seizures Now Available in U.S. Pharmacies|
|3/3/14||Sunovion and Takeda Announce Results from a New Study Showing Maintenance Treatment with Lurasidone Reduced the Risk of Relapse in Adults with Schizophrenia|